Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc.

Patheon

Thermo Scientific

FEI Company

Accelerating Microscopy

Chromatography & Mass Spectrometry

Unity Lab Services

Fisher Healthcare

Advancing Materials

Thermo Fisher Spectral Cytometry

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. 

For more information, please visit www.thermofisher.com.

National Grid

Thermo Fisher Scientific

For the sixth consecutive year, the #DisabilityEqualityIndex from Disability:IN has recognized Thermo Fisher as one of the "Best Places to Work for People with Disabilities." Our global colleagues are our greatest asset and we are incredibly proud to be recognized for creating a culture where each of our employees is valued.

“When it comes to gene editing, the next 10 years will bring new therapy approvals, many clinical trials and lessons learned across the industry.” With a number of #genediting treatments nearing approvals, patients may soon have access to these potentially curative treatments. Read what the industry must overcome to bring gene editing to market in a new Technology Networks article from Jason Potter, director of cell biology R&D. https://lnkd.in/gABuZPs9 #CRISPR

#Preeclampsia affects about one in 25 pregnancies, and the condition has been rising in the United States. The New York Times reporter, Roni Caryn Rabin, writes about our recently FDA-cleared blood test for preeclampsia that experts say is the “first advance in diagnosing the deadly condition since it was discovered more than a century ago.” View the story here: https://lnkd.in/eFN5CrDh

We've announced an agreement to acquire CorEvitas, LLC,  a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. CorEvitas’ real-world evidence solutions provides pharmaceutical and biotechnology companies with objective data and clinical insights to improve patient care and clinical outcomes. Upon completion, this will expand our clinical research capabilities to enable our customers to accelerate innovation and drive productivity. Learn more: https://lnkd.in/gV2kSNs5

AI allows us to rethink how we integrate information, analyze data, and use the resulting insights to improve decision making in almost every facet of our lives. Our Chief Human Resources Officer, Lisa Britt, recently spoke with Fortune @ Work on the endless opportunities to use generative A.I. to help us further innovate. Read her comments on how our colleagues will leverage A.I. while protecting our confidential information and important human values [Subscription Required]: https://lnkd.in/gYmviERk

Pride Month brought many of our global colleagues together to celebrate virtually and in person. From Bulgaria to Costa Rica, pictured are just a few of our many Pride+ Business Resource Group (BRG) chapters bringing the month’s theme, “Love the Science of You”, to life through a full calendar of events. The events provided opportunities to connect and have fun, while building a sense of community and belonging. 
 
#PrideMonth2023

This week, our team in Germering, Germany gave U.S. Consul General Timothy Liston a first-hand look into how we fulfill our mission through our products and services and our commitment to environmental stewardship. Thermo Fisher leaders shared how this site supports our customers with everything from drug discovery to food and beverage testing and manufacturing to environmental and industrial testing. The team also discussed how the Germering site is a leading example of our net-zero efforts by being a fossil fuel free facility operating on 100% renewable electricity.

Boys & Girls Clubs of America is our longtime partner in nurturing a STEM workforce that reflects the diversity of the world around us. In celebration of National Boys & Girls Club Week and BGC Great Futures Day, we co-hosted Blast Off to Great Futures: Space Bound, Safe and Sound, an out-of-this-world STEM education event for Club kids from Boys & Girls Clubs of Western Pennsylvania. Special thanks to our colleague volunteers for guiding Club kids through the activities, and to the Carnegie Science Center  for the inspiring content and facilitation.
 
“As an alum of Boys & Girls Clubs, I have really fond memories of building relationships, laughing and learning with a bunch of kids from my community,” said Mike Fuchs, event volunteer and Vice President Commercial, Research and Safety Americas, Customer Channels, Thermo Fisher Scientific. “This [event] gives us a great platform to engage students and influence young minds.”
 
Learn about our award-winning partnership with Boys & Girls Clubs of America: thermofisher.com/bgca 
#thisisBGC #BGCweek2023 #greatfutureswithBGC

We are committed to inspiring the next generation of innovators through #STEMeducation! Our Viral Vector Services colleagues in Plainville, Massachusetts recently wrapped up a fantastic mentoring program with children from the town of Plainville’s Beatrice Wood Elementary School. More than 30 mentors from the site volunteered each week, sharing inspiring stories and educating them on the great possibilities of science.
 
Thank you North TV for this video that highlights the impact of the program: https://lnkd.in/gh5DxwtX

Innovations in mass spectrometry are empowering scientists to make breakthrough discoveries more efficiently than ever. This article in Technology Networks highlights how novel technology is powering what’s next for proteomic researchers working toward a more personalized approach to healthcare. Learn more: https://lnkd.in/gzXUqMFR

NYSE:TMO

Thermo Fisher Scientific Inc.

Last Close

611.68

30/08 20:00

Market Cap

204.93B

Beta: 0.79

Volume Today

1.06M

Avg: 1.25M

PE Ratio

35.85

PFCF: 32.57

Dividend Yield

0.25%

Payout:8.48%